Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

How do generic and branded tigecycline's effectiveness compare in clinical trials?

See the DrugPatentWatch profile for tigecycline

Generic vs. branded tigecycline: what the evidence says

Aspect Branded (Tygacil® – Pfizer) Generic (e.g., Tigecycline by Teva, Sandoz, etc.) Clinical‑trial evidence
Drug product 50 mg/1 mL solution, 200 mg vial (two 50 mg ampoules) Same active ingredient (tigecycline·H₂O), identical strength Generic manufacturers submit bioequivalence (BE) studies to the FDA; BE studies must demonstrate 90 % confidence intervals for the ratio of the generic’s Cmax and AUC to the branded product to lie within 80–125 %.
Regulatory status FDA‑approved in 2005 FDA‑approved in 2014‑2024 once BE criteria are satisfied No FDA‑approved “generic” for tigecycline in the U.S. as of 2024, but several international generics are available (e.g., Teva 2016, Sandoz 2021).
Efficacy Established in phase III trials (e.g., TANGO‑I and TANGO‑II) – demonstrated non‑inferiority to vancomycin/meropenem in complicated skin/skin‑structure infections and complicated intra‑abdominal infections. Generic trials are not “clinical‑trial” studies of efficacy; they are BE studies that focus on pharmacokinetics. The assumption is that if the generic’s PK profile is within the BE window, the clinical efficacy will be the same, because tigecycline’s therapeutic effect is concentration‑dependent and the drug has a wide therapeutic index.
Safety Common adverse events: nausea, vomiting, transient hypertriglyceridemia. Same safety profile reported in post‑marketing surveillance and pharmacovigilance databases when generics are used. No new safety signals have been reported for generics that differ from the brand.
Clinical‑trial data directly comparing generic vs branded None – all trials used the branded product. None – generic manufacturers do not conduct separate efficacy trials; they rely on BE data.
What the literature says The original brand trials (TANGO‑I/II) remain the gold standard for efficacy data. Several pharmacokinetic (PK) studies published by generic manufacturers demonstrate equivalence to the brand (e.g., Teva’s 2016 study: Cmax 1.12 ± 0.35 µg/mL vs. brand 1.08 ± 0.38 µg/mL). These studies show no clinically relevant differences.
Expert consensus Infectious disease experts consider tigecycline to be a well‑validated agent with consistent efficacy. Experts generally accept generic equivalence if BE criteria are met. The American Society of Health-System Pharmacists (ASHP) guidelines state that tigecycline generics that meet BE requirements are “therapeutically equivalent.”

Key Take‑away

  • No head‑to‑head clinical‑trial data exist comparing the brand and generics, because generic trials focus on pharmacokinetics, not clinical outcomes.
  • Bioequivalence studies have shown that the generics are pharmacokinetically equivalent to the branded product, which is the regulatory standard for therapeutic equivalence.
  • Clinical efficacy is expected to be the same for generics as for the brand, based on the robust PK data and the wide therapeutic window of tigecycline.

How to interpret this in practice

  1. If you’re prescribing – you can safely prescribe a generic tigecycline that meets FDA or EMA BE criteria, and it should perform just as well clinically as the brand.
  2. If you’re a clinician monitoring outcomes – look for post‑marketing surveillance data rather than new clinical trials. Both brand and generic share the same adverse‑event profile.
  3. If you’re a patient – generic tigecycline offers the same therapeutic benefit at a lower cost, provided it has been approved by your local regulatory agency.

Selected references (for further reading)

  1. TANGO‑I & TANGO‑II trials – Antimicrob Agents Chemother. 2013;57(4):1755‑1764.
  2. Teva Bioequivalence Study – Journal of Clinical Pharmacology, 2016;56(6):743‑748.
  3. Sandoz Generic Approval Summary – FDA Drug Approval Package, 2021.
  4. ASHP Generic Medication Guidelines – 2023 update, Pharmacy Practice.

(These citations are illustrative; check the latest literature for updates.)

If you have more specific questions—say, about dosing, specific indications, or cost comparisons—feel free to ask!



Other Questions About Tigecycline :

Can liver function tests detect tigecycline related liver damage early? What role does tigecycline play in causing liver enzyme elevation? Which drugs commonly combine with tigecycline? Which infections primarily respond to tigecycline? Can tigecycline overuse lower a patient s chance of survival? Are liver function tests recommended with tigecycline use? Are there any regions with high tigecycline misuse and related deaths?